Plenary

- Judith Graham Pool Memorial Lecture – Gene Therapy in Hemophilia: Will There be a New Era in Hemophilia Treatment?
- Marion I. Barnhard Memorial Lecture – From Bench to Bedside: P-Selectin Blockade in Sickle Cell Disease
- Sol Sherry Memorial Lecture – Hormones and Thrombosis

State-of-the-Art

- Contact Pathway – Pathogenic Factor XII Mutations: Form Determines Dysfunction
- Contact Pathway – FXII Regulation and Inhibition
- Contact Pathway – FXI and FXII Structural Biology
- Arterial Thromboembolism – Advanced Imaging
- Hemostatic Complications of Pregnancy – Complement Dysregulation in Pregnancy
- Cancer Immunotherapy and Coagulation – Endothelial Activation During CD19 CAR-T Cell Therapy
- Cancer Immunotherapy and Coagulation – Hemostatic Factors and Tumor Immunity – a Double Edged Sword
- Structural Determinants of Function – VWF Structure-Function in the Regulation of Cancer Metastasis
- Hot Topics in Neonatal and Pediatric Thrombocytopenia – The Role of Platelet Transfusions to Manage Bleeding: Lessons From Randomized Trials (Including Neonates and Children)
- Hot Topics in Neonatal and Pediatric Thrombocytopenia – Platelets in the Neonate: Not Just a Small Adult
- Novel Aspects of Fibrinogen in Disease – Fibrin(ogen) in Human Disease
- Mechanisms of Thrombosis in Cancer and Clonal Disorders – Role of Exosomes and Exomerases in Cancer and Coagulation
- Mechanisms of Thrombosis in Cancer and Clonal Disorders – Clonal Hematopoiesis and Thrombosis
- Mechanisms of Thrombosis in Cancer and Clonal Disorders – Mechanistic Insights From 3-D Visualization of Thrombus Formation in Cancer
- COVID and Coagulation in 2021 – Vaccine-Induced Thrombocytopenia and Thrombosis: Current Thoughts on Mechanism and Management
- Vascular Permeability and Inflammation – Vascular Inflammatory Responses
- Vascular Permeability and Inflammation – VEGF and Vascular Permeability
- Novel Mechanisms Driving Arterial Thromboembolism – Lp(a) as a Novel Target for Thrombosis
- Effect of Health and Disease States on VWF/VWD – Understanding Acquired VWD in Cardiovascular Disorders: From Pathophysiology to Patient Care
- Effect of Health and Disease States on VWF/VWD – Pregnancy, Postpartum and Periods: Current Challenges in the Management of Women With VWD
- Cell-Dependent Fibrinolysis and Proteolysis – Fibrin(ogen)-Endothelial Cell Interactions in Inflammation
• Cell-Dependent Fibrinolysis and Proteolysis — Cellular Aspects of Thrombus Resolution
• Thromboembolism in Women — DOACs in Pregnancy: The ISTH Registry and Beyond
• Frontiers of OMICS — Platelet Lipidomics and Signaling
• Frontiers of OMICS — Microbiota and Thrombosis
• New Concepts in Pediatric Thrombosis — Peripheral Arterial Thrombosis in Children
• New Concepts in Pediatric Thrombosis — Pulmonary Embolism in Children
• Platelets in Infectious Disease — Platelets: Influenza and Other Viral Responses
• Platelets in Infectious Disease — Platelet-Leukocyte Interactions in COVID-19: Contributions to Inflammation, Hypercoagulability and Disease Severity
• Translational Research in Rare Bleeding Disorders — Rationale Design of Therapeutics in Hemophilia
• Cancer-Associated VTE — Treatment of Cancer-Associated VTE: Drugs, Duration
• Cancer-Associated VTE — Myeloproliferative Neoplasm-Associated Thrombosis
• Biology of the Endothelium — Flow-Dependent Endothelial Cell Functional Phenotypes
• Biology of the Endothelium — Vascular Hemodynamics and Malformations
• New Insights Into Megakaryocyte and Platelet Biology — iPS Cells and New Insights Into Inherited Platelet Disorders Associated With an Increased Risk of Malignancies
• Dynamic Regulation of Blood Coagulation — Intermolecular Interactions that Stabilize Multimeric FXIII
• Dynamic Regulation of Blood Coagulation — Structural Basis of Antagonizing the Vitamin K Catalytic Cycle for Anticoagulation

Oral Communication

• Interplay Between Hemostasis and Inflammation — Podocyte tissue factor suppresses spontaneous sterile renal inflammation
• Molecular and Genetic Mechanisms in Fibrinolysis — Granulocyte Microvesicles with a High Plasmin Generation Capacity Promote Clot Lysis and Improve Outcome in Septic Shock
• Molecular and Genetic Mechanisms in Fibrinolysis — Controlled Long-term Knockdown of Plasminogen in Mice and Dogs using siRNA: Assessment of Phenotype and Toxicity
• Mechanisms of Thrombosis in COVID-19 — Biphasic thrombus development during coronavirus infection
• Mechanisms of Thrombosis in COVID-19 — SARS-CoV-2 infection of K18-hACE2 transgenic mice induces an early hyperactive phenotype in circulating platelets
• Mechanisms of Thrombosis in COVID-19 — Lipid-binding antiphospholipid antibodies trigger autoimmune signaling in severe COVID-19
• OMICS — High throughput sequencing for the molecular diagnosis of inherited platelet disorders in Spain. Experience of the GEAPC group
• OMICS — 13C Metabolic Flux Analysis in Resting and Thrombin Activated Platelets
• Molecular Mechanisms of Coagulation — A novel prediction platform to enhance the design of therapeutic SERPINs
• Molecular Mechanisms of Coagulation — Evolutionary Adaptation of the Gamma-carboxyglutamic Acid Domain in Venom Factor X from the Australian Common Brown Snake
• Anticoagulants for the Treatment and Prevention of Cancer-Associated Thrombosis – Improved overall survival with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism: A SEER-Medicare analysis
• Hemophilia: Real World Data – Long-term outcomes in adolescents with moderate or severe hemophilia A: A PedNet study
• VWF Structure and Function – Piggyback knockdown screen of glycosyltransferases in zebrafish: identification of novel regulators of von Willebrand factor levels
• VWF Structure and Function – Structure of the von Willebrand Factor C6 domain and effect of variant p.Gly2705Arg
• Platelet Receptors and Signaling I – Regulation of P2Y receptor expression and activity by cAMP mediated PKA signalling in human platelets; a novel mode of action of anti-platelet drugs?
• Platelet Receptors and Signaling I – Impairment of Platelet Purinergic Signaling in Sickle Cell Disease
• Platelet Receptors and Signaling I – Platelet proteome and variability in the responsiveness to low-dose aspirin in patients with cardiovascular disease
• Platelets, Thrombosis and Hemostasis – Platelet Binding to Polymerizing Fibrin is Avidity-Driven and Requires Activated αIIbβ3
• Platelets, Thrombosis and Hemostasis – Active sorting of platelets and red blood cells in contracting blood clots is driven by platelet-generated forces that stiffen fibrin
• Platelets, Thrombosis and Hemostasis – Force-Independent Cleavage of Talin by Calpain Promotes Platelet-mediated Fibrin Clot Contraction
• Bleeding and Mortality in Patients with Cancer-Associated Thrombosis – Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban: results from the Hokusai VTE Cancer study
• Inherited and Acquired VWD – Shear-induced platelet-GPIbα shedding under extracorporeal membrane oxygenation promotes thrombocytopenia independently from von Willebrand factor
• Inherited and Acquired VWD – Response to treatment for gastro-intestinal bleeding in patients affected by Von Willebrand disease
• Platelet, Neutrophil and Complement Responses to COVID-19 – Altered platelet proteome and platelet-leukocyte interactions in patients with COVID-19
• Vascular Cells and Coagulation I – From coagulation to angiogenesis: extra-coagulative role of FVIII
• Vascular Cells and Coagulation I – Regulation of endothelial cell procoagulant activity by TMEM16 scramblases
• Vascular Cells and Coagulation I – Specialized SPARC-forming regulatory T cells control venous blood clot degradation
• Vascular Cells and Coagulation I – A Mouse Model of Protease Activated Receptor 4 (PAR4) variant rs2227376 Has Reduced Platelet Reactivity to Physiological Doses of Thrombin
• Coronary Artery Disease from Genes to Stents – Pharmacodynamics of Bolus With and Without Infusion of Cangrelor in Healthy Volunteers: a dose-finding, open-label, pilot trial
• Diagnostic and Coagulation – Haemostatic components are associated with risk of venous thromboembolism after lower leg trauma
• Genetics of VTE – The R543L Protein Altering Variant in the FII Gene (F2) Is a Major Determinant of Coagulation Potential in Mexican Americans
• Bleeding and Thrombosis in Neonates – The Effect of Platelets on Thrombin Generation in the Premature Infant: The EVENT Study
- **Novel Diagnostic Aspects of Platelet Disorders** – Diagnosing inherited platelet disorders: immunofluorescence on the blood smear in comparison with genetic testing
- **Fibrinogen and Factor XIII in Disease** – Genetic Truncation of the Fibrinogen αC-region in Mice Results in Severe Hypofibrinogenemia with Preservation of Hemostasis and Protection from Venous Thrombosis
- **Fibrinogen and Factor XIII in Disease** – Mechanisms coupling fibrinogen to colitis pathogenesis
- **Risk Assessment in Cancer-Associated Thrombosis** – Personalized Cancer-Associated Thrombosis Risk Assessment: Integration of plasma proteomics, clinical characteristics, and machine learning
- **Risk Assessment in Cancer-Associated Thrombosis** – The prognostic value of symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism: analysis of an international, prospective, observational cohort study
- **Hemophilia: Basic Science** – Evaluation of the Tissue Factor-Independent Mechanism of Action for Eptacog Beta
- **Hemophilia: Basic Science** – Neutralizing and Non-neutralizing Anti-FVIII Antibodies in Black and White Hemophilia A Subjects: A Natural History Profile
- **Health Outcomes in VTE** – Trends in venous thromboembolism and death in COVID-19 positive patients in 2020
- **Hemostatic Agents and Hemostatic Efficacy** – Efficacy and Safety of Valoctocogene Roxaparvovec Adeno-associated Virus Gene Transfer for Severe Hemophilia A: Results from the Phase 3 GENER8-1 Trial
- **Hemostatic Agents and Hemostatic Efficacy** – Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B
- **Hemostatic Agents and Hemostatic Efficacy** – PLASMIN-RESPONSIVE PROCOAGULANT SYNTHETIC PLATELETS FOR FIBRIN CLOT STABILIZATION IN HEMORRHAGE CONTROL
- **Regulation of Activated Protein C and Factor V** – Kallikrein augments the anticoagulant function of protein C system in thrombin generation
- **Vascular Cells and Coagulation II** – Inhibition of Neutrophil Extracellular Traps Reveals their Differential Role in the Pathogenesis of Abdominal Aortic Aneurysms in Distinct Mouse Models
- **Megakaryopoiesis and Platelet Life Cycle, I** – Early endosomal GTPase Rab5 regulates GPIb trafficking and platelet production <em>in vitro</em>
- **Megakaryopoiesis and Platelet Life Cycle, I** – Loss of G6b-B confines megakaryocyte differentiation potential and promotes osteosclerosis in mice
- **Megakaryopoiesis and Platelet Life Cycle, I** – Transcriptomics and proteomics to study the effect of hyperactive SRC kinase during megakaryopoiesis
- **Mechanisms and Genetics of Cancer-Associated Thrombosis** – Podoplanin and tissue factor cooperate in triggering microthrombosis in experimental glioblastoma and are released to systemic circulation as cargo of extracellular vesicles
- **Mechanisms and Genetics of Cancer-Associated Thrombosis** – Tumor gene expression associates with venous thromboembolism in patients with pancreatic cancer
- **Mechanisms and Genetics of Cancer-Associated Thrombosis** – <em>CDKN2A</em> mutational status is associated with venous thromboembolism in patients with glioblastoma
- **Novel Findings of Inherited Platelet Disorders** – Characterization of a new family with lifelong macrothrombocytopenia caused by a novel nonsense variant in <em>TPM4</em>
- **Novel Biotherapeutics in Hemophilia: Clinical** – Emicizumab prophylaxis and monitoring: real world data
- Novel Biotherapeutics in Hemophilia: Clinical – Long-Term Safety and Efficacy of the Anti-TFPI Monoclonal Antibody Marstacimab in Patients With Severe Haemophilia A or B: Results From a Phase 2 Long-term Treatment Study
- Complications of Pregnancy – Are Antiphospholipid Antibodies a Poor Prognostic Factor for HELLP Syndrome?
- Risk Factors for VTE – The role of acute-phase circulating miRNAs in modulating clinical outcome in patients with venous thromboembolism
- Risk Factors for VTE – Pregnancy from In Vitro Fertilization is Associated with Increase in Risk of Venous Thromboembolism When Compared to Normal Pregnancy: A Systematic Review and Meta-Analysis
- TFPI-Regulation and Function – Platelet TFPIα Dampens Prothrombotic and Fibrotic Responses to Radiation Injury in Mouse Heart
- TFPI-Regulation and Function – Protein S Coordinates the Synergistic Inhibition of Prothrombinase by Tfpia and Activated Protein C
- TFPI-Regulation and Function – Protein arginine deiminase 4 inactivates tissue factor pathway inhibitor by post-translational modification of functional arginine residues
- TFPI-Regulation and Function – A Major Reservoir for Heparin-Releasable TFPIα is Extracellular Matrix
- Platelet Receptors and Signaling II – Affimers modulate GPVI interactions with collagen/fibrinogen and GPVI-mediated platelet aggregation
- The Immune Response to Factor VIII – Oral delivery of factor VIII reduces the magnitude of the anti-FVIII immune response and increases splenic Treg numbers
- The Immune Response to Factor VIII – BAFF Inhibition Prevents FVIII Inhibitor Formation in a Marginal Zone B Cell-independent Manner
- Hemostatic Problems in Pediatric ECMO and COVID-19 Patients – Acquired von Willebrand Disease in Pediatric Patients Undergoing ECMO Support
- Hemostatic Problems in Pediatric ECMO and COVID-19 Patients – Platelet Fibrinogen Receptor Expression and Platelet Function Decreases as Duration of ECMO Increases in Paediatric Veno-arterial ECMO Patients
- Hemostatic Problems in Pediatric ECMO and COVID-19 Patients – Novel, point-of-care coagulation test detects anticoagulation resistance predictive of thrombotic events in pediatric ECMO patients
- Tumor Growth and Hemostasis I – The Factor XII-uPAR Axis Drives Ovarian Cancer Maintenance and Progression
- Tumor Growth and Hemostasis I – Plasminogen, but Not Fibrinogen, Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth and Metastasis
- Tumor Growth and Hemostasis I – The Role of the Thrombin/PAR axis in the Anti-Tumor CD8+ T cell Response following Immune Checkpoint Inhibition Therapy
- Cellular and Molecular Functions of Fibrinogen and Factor XIII – Cellular factor XIII in macrophage derived foam cells
- Cellular and Molecular Functions of Fibrinogen and Factor XIII – Controlled knockdown of fibrinogen with siRNA modulates fibrinogen-mediated inflammation
- Cellular and Molecular Functions of Fibrinogen and Factor XIII – Cryoprecipitate transfusion significantly decreases the rate of plasmin generation in trauma patients
- VWF and ADAMTS13 – Inhibition of ADAMTS13 Rescues Acquired von Willebrand Syndrome in a Preclinical Left Ventricular Assist Device Animal Model
- VWF and ADAMTS13 – ADAMTS-13/VWF RATIO AS BIOMARKER FOR PORTAL VEIN THROMBOSIS (PVT) DEVELOPMENT IN CIRRHOTIC PATIENTS: A PROSPECTIVE STUDY
- Antiphospholipid Antibodies and Antiphospholipid Syndrome – Progression of ischaemic and haemorrhagic brain lesions on MRI in APS patients on antithrombotic therapy
- Antiphospholipid Antibodies and Antiphospholipid Syndrome – Origin of Antiphospholipid Antibodies in Autoimmunity and viral infection
- Modulation of Hemostasis-Clinical Assessment – Growth differentiation factor-15 for prediction of bleeding in cancer patients
- Modulation of Hemostasis-Clinical Assessment – VMX-C001 is an effective FXa-DOAC reversal agent and displays no thrombogenic potential in comparison to andexanet alfa and 4PCC
- Platelet Biology in Prothrombotic Disorders – Prevention of thrombocytopenia and thrombosis in heparin-induced thrombocytopenia (HIT) using deglycosylated KKO: A novel therapeutic for HIT?
- Platelet Biology in Prothrombotic Disorders – A Thrombospondin-1 Release Assay (TRA) Coupled to PF4-treated Frozen Platelets is Highly Accurate for the detection of Pathogenic HIT antibodies: Implications for Development of a Near-patient HIT In Vitro Diagnostic Assay
- Platelet Biology in Prothrombotic Disorders – Features of Aspirin-Resistant Biomechanical Platelet Activation in Fibromuscular Dysplasia
- Novel Biotherapeutics in Hemophilia: Laboratory – A blood coagulation factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma
- Bone and Joint Health in Hemophilia – BONE DISEASE IN HEMOPHILIA: THE ROLE OF DIFFERENT BONE CELLS
- Bone and Joint Health in Hemophilia – Joint Status of Patients with Non-Severe Hemophilia A
- New Diagnostics – Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay to estimate levels of direct oral Xa inhibitors in ex-vivo patient samples
- New Diagnostics – Paediatric D-dimer and Fibrin Degradation Products (FDP) Reference Intervals Using STA® Liatest D-Di Plus and STA® Liatest FDP
- New Diagnostics – Measurement of von Willebrand factor levels via fiber optic-surface plasmon resonance
- Platelet Interactions with Neutrophils and the Endothelium – The importance of the \text{GPIb}α intracellular tail in VWF-mediated platelet signaling events and platelet/neutrophil interactions
- TTP Across the Age Continuum – Anti-ADAMTS13 Antibodies in Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)
- Contact Pathway-Molecular Regulation and Clinical Assessment – A mechanism for hereditary angioedema caused by a plasminogen Lys311Glu substitution
- Inhibitors in Hemophilia A – IgG2 as hallmark of inhibitor persistence in a longitudinal analysis of PUPs in the first 50 exposure days to FVIII
- Inhibitors in Hemophilia A – No difference in inhibitor incidence in Previously Untreated Patients (PUPs) with severe and moderately severe Hemophilia A treated with a third-generation recombinant factor VIII when compared with plasma-derived factor VIII
- Genetics and Gene Therapy in Hemophilia – Comparative analysis of residual factor VIII expression from recurrent \text{F8} nonsense mutations indicates that localization in the B-domain favours readthrough-mediated protein output
- Genetics and Gene Therapy in Hemophilia – Identification and characterization of \text{F9} deep intronic variations in haemophilia B patients
• Genetics and Gene Therapy in Hemophilia – <em>F8</em> genetic variants associated with inhibitor development in a multiethnic population of non-severe hemophilia A
• Tumor Growth and Hemostasis II – The “double-edged sword”: the role of LMWPTP in platelet hyperactivity in cancer patients
• Tumor Growth and Hemostasis II – Delineating the role of low molecular weight heparin in breast cancer metastasis
• Tumor Growth and Hemostasis II – Platelets Stimulate Programmed Death-Ligand 1 Expression by Cancer Cells: Inhibition by Anti-Platelet Drugs
• Rare Bleeding Disorders – Oral Pazopanib Results in Durable Hemostasis in Patients with Severe Bleeding and RBC Transfusion-Dependent Hereditary Hemorrhagic Telangiectasia
• Rare Bleeding Disorders – Hemostatic treatment of patients with rare bleeding disorders in the Netherlands: real-life data from the RBiN study
• Anticoagulants: Novel Strategies and Mechanisms – A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating Safety and Efficacy of AB023 in Hemodialysis Patients
• Anticoagulants: Novel Strategies and Mechanisms – Antithrombotic potential of a single-domain antibody enhancing the anticoagulant activity of protein S
• Anticoagulants: Novel Strategies and Mechanisms – Targeting coagulation factor Xa and IIa differentially regulate inflammation
• Anticoagulants: Novel Strategies and Mechanisms – Discovery and in vitro Characterization of an Antibody Fragment (Fab) which Neutralizes Milvexian (BMS-986177/JNJ-70033093)
• Platelet Biology – Pleiotropic Role of miR-146a in Driving Metabolism Reprogramming Causes Platelet Hyperreactivity and Thrombosis
• Platelet Biology – Dense granules are released cooperatively in activated platelets
• Platelet Biology – A novel particle-based model delivers mechanistic insights into arterial thrombus heterogeneity
• Platelet Biology – Understanding the role of mitochondria in platelet function
• Critical Hemostatic Issues with Childbirth – Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: a multicenter prospective cohort study in the Netherlands
• Diagnosis of VTE – Diagnosis of Acute Pulmonary Embolism across Different Healthcare Settings: A Systematic Review and Individual Patient Data Meta-Analysis
• Residual Venous Obstruction and Post-Thrombotic Syndrome – 25mmHg vs. 35mmHg Elastic Compression Stockings to Prevent Post Thrombotic Syndrome after Deep Vein Thrombosis: The CELEST double-blind trial
• Risk and Prevention of Stroke in Atrial Fibrillation – Improving outcomes with integrated care of patients with atrial fibrillation and multimorbidity using mobile health technology: A report from the mAFA II trial
• ADAMTS13, Complement and Thrombotic Microangiopathies – Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura
• ADAMTS13, Complement and Thrombotic Microangiopathies – Von Willebrand Factor Contributes to Alternative Complement Pathway Activation, Microangiopathy, and Renal Dysfunction in Murine Thromboinflammation
• ADAMTS13, Complement and Thrombotic Microangiopathies – Development of an easy-to-use ADAMTS13 conformation assay using fiber optic surface plasmon resonance technology
• Safety and Efficacy in Gene Therapy for Hemophilia – Hemostatic Response is Maintained for up to 5 Years Following Treatment with Valoctocogene Roxaparvovec, an AAV5-hFVIII-SQ Gene Therapy for Severe Hemophilia A
• Safety and Efficacy in Gene Therapy for Hemophilia – Clinical Outcomes in Adults with Hemophilia B With and Without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial
• SARS-CoV2 and the Endothelium – Circulating levels of platelet, endothelial and red blood cell microvesicles in COVID-19: association with biomarkers of coagulation, fibrinolysis and angiogenesis
• Pathogenesis and Management of Pediatric Thrombosis – Pediatric leukemic lymphoblasts produce hemostatic system factors: a novel contributor to the hemostatic imbalance in pediatric acute lymphoblastic leukemia
• Modulation of Coagulation and Disease – Apolipoprotein A-IV polymorphisms Q360H and T347S reduce its inhibitory effect against thrombosis
• Pulmonary Embolism: Diagnosis, Prognosis and Management – Prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry
• Pulmonary Embolism: Diagnosis, Prognosis and Management – Use of the National Early Warning Score for predicting deterioration of patients with acute pulmonary embolism
• Megakaryopoiesis and Platelet Life Cycle, II – Evolution of the tubulin post-translational modification repertoire during megakaryopoiesis
• Megakaryopoiesis and Platelet Life Cycle, II – β1 and β3 integrins limit the passage of entire megakaryocytes across the sinusoids of the bone marrow
• Megakaryopoiesis and Platelet Life Cycle, II – Platelets preferentially bind senescent red blood cells and regulate in their clearance
• Basic and Laboratory Aspects of Gene Therapy for Hemophilia – Prenatal Therapy with Placental Cells Transduced with an Engineered fVIII Transgene Results in Curative fVIII Plasma Levels for 3 Years after Birth, Without Immune- or Toxicity-Related Adverse Events
• Basic and Laboratory Aspects of Gene Therapy for Hemophilia – AAV Delivery of a Novel Human Factor VIII Variant with Improved Secretion Results in Higher FVIII Expression in Hemophilia A Dogs
• Effectiveness and Safety of Anticoagulants for VTE – Effectiveness and Safety of Apixaban vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Thrombophilia
• Effectiveness and Safety of Anticoagulants for VTE – Safety and efficacy of the direct oral anticoagulants in cerebral vein thrombosis: a systematic review and meta-analysis
• Thrombo-Inflammation and Disease – Monocyte-macrophage synthesis of FVII contributes to the development of atherosclerosis
• Thrombo-Inflammation and Disease – Coagulation factor XII signaling via uPAR-β1 integrin promotes renal tubular senescence in diabetic nephropathy
• Thrombo-Inflammation and Disease – Thrombin mediated activation of protease activated receptor 1 contributes to doxorubicin induced cardiac injury
• Late-breaking Abstract Session I – A Six-week versus Three-month Duration of Anticoagulation for Acute Provoked Venous Thromboembolism in Patients < 21 Years Old: Results of the Multinational Kids-DOTT Randomized Controlled Trial
• Late-breaking Abstract Session II – Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
• Late-breaking Abstract Session II – Mechanism of the development of thrombotic thrombocytopenia in Covid-19 infected patients and after vaccination

Nurses Forum

• Nurses Forum – Antithrombotic Therapy: A Focus on Psychosocial Impact

SSC Sessions

• Factor VIII, Factor IX and Rare Coagulation Disorders – In Patients on Non-Factor Therapies, Exposure to Clotting Factor Replacement Should Be Early (Debate)
• Factor VIII, Factor IX and Rare Coagulation Disorders – Anti Adeno-Associated Virus Antibodies Antibodies: What Are the Standardization Issues?
• Factor VIII, Factor IX and Rare Coagulation Disorders – Non-Factor Replacement Therapy Versus Factor Replacement Therapy Risks -There Is No Free Lunch (Debate)
• Factor VIII, Factor IX and Rare Coagulation Disorders – Beyond Annualized Bleed Rates What Should Be the Alternative Endpoints for Non-Replacement Therapies
• Platelet Immunology – Update on the SSC Survey On the Postnatal Fetal and Neonatal Alloimmune Thrombocytopenia
• Platelet Immunology – Summary and Roadmap
• Platelet Immunology – Standardization of Functional Heparin Induced Thrombocytopenia Assays
• Platelet Immunology – Platelet Activating Immune Complexes in COVID-19
• Vascular Biology – Standardization of Extracellular Vesicle Concentration Measurements - An Update on the METVES II Project
• Vascular Biology – Extracellular Vesicle-Tissue Factor Assays in COVID-19 Time
• Vascular Biology – Endothelial Senescence in Chronic Lung Disease and Possible Implications in Severe COVID-19: Studies on ECFC
• Vascular Biology – Establishment of a Flow Cytometric Panel for the Characterization of Factor X Expressing Tumor Macrophages in Mice
• Vascular Biology – Enzyme-Linked Immunoassay (ELISA) Detection of MPO-DNA Complexes in Human Plasma
• Vascular Biology – Endothelial Cells and COVID-19: Marker or Active Partner
• Lupus Anticoagulant/Antiphospholipid Antibodies – Update on the SKYLARK Project (Successive Follow up of Antiphospholipid Antibodies Fluctuations in Patients With Clinical Sydney Criteria for Antiphospholipid Antibody Syndrome) and the Nymphea Project (Antiphospholipid Antibodies and Lymphoma)
• Lupus Anticoagulant/Antiphospholipid Antibodies – Current Treatments Practice in Women With Obstetric Antiphospholipid Antibody Syndrome and Women With Obstetrical Morbidity and “Non-Criteria” Antiphospholipid Antibody Syndrome and Adverse Obstetrical Outcomes: Cora International Registry
• Lupus Anticoagulant/Antiphospholipid Antibodies – Standardization of Thrombin Generation Assays
• Lupus Anticoagulant/Antiphospholipid Antibodies – Qualitative Classification of Anticardiolipin and Anti-beta2glycoprotein I Antibodies
- Women’s Health in Thrombosis and Hemostasis – ISTH Guidance on Diagnosis and Management of Severe Congenital Protein C Deficiency - Joint SSCs Project
- Women’s Health in Thrombosis and Hemostasis – Women International TEAM (WiTEAM) Study on Placenta-Mediated Pregnancy Complications and Thrombophilia
- Women’s Health in Thrombosis and Hemostasis – Physicians’ Knowledge and Practices of Management of COVID-19 Coagulopathies in Pregnancy
- Fibrinolysis – Update on SSC Project: The Assessment of Fibrinolytic Resistance in Septic Patients Using the Rotem Velocity Curves of Clot Formation
- Von Willebrand Factor – Project Updates: Post Partum Hemorrhage
- Von Willebrand Factor – ADAMTS13 Auto-Antibody Binding
- Von Willebrand Factor – Pathogenesis of Microthrombi in SARS-CoV2 Infection: Role of Von Willebrand Factor and ADAMTS-13
- Von Willebrand Factor – Towards a Unifying Activation Mechanism of Von Willebrand Factor
- Pediatric/Neonatal Thrombosis and Hemostasis – Update From the Emerging Working Group on ExtraCorporeal Life Support/Ventricular Assist Device
- Pediatric/Neonatal Thrombosis and Hemostasis – Update From Antithrombotic Trials Task Force
- Pediatric/Neonatal Thrombosis and Hemostasis – Update From Medication Adherence Working Group
- Perioperative and Critical Care in Thrombosis and Hemostasis – Perioperative Bleeding: Platelet Transfusions and Alternatives
- Perioperative and Critical Care in Thrombosis and Hemostasis – Heparin Resistance: Definitions, Clinical Considerations, and Alternative Strategies
- Factor XIII and Fibrinogen – Comprehensive Evaluation of Coagulation and Fibrinolysis Parameters in Patients With Congenital Factor XIII Deficiency in Pakistan - an Introduction and Outline of the SSC Project
- Factor XIII and Fibrinogen – Standardisation of Scanning Electron Microscope Image Analysis of Fibrin Clots - SSC Project
- Biorheology – Thrombosis on Artificial Materials: Extracorporeal Circuits and Beyond
- Biorheology – Valve Thrombosis in Trans-Catheter Aortic Valves: Influence of Patient Anatomy
- Biorheology – Thrombosis in Mechanical Circulatory Support
- Plasma Coagulation Inhibitors – Which Test to Choose: Activated Protein C Resistance First or Factor V Leiden Directly?
- Pediatric/Neonatal Thrombosis and Hemostasis – Update From Duration of Antithrombotic Therapy Working Group (on behalf of H. Wilson)
- Plasma Coagulation Inhibitors – Developmental Changes in the Protein C Structure
- Plasma Coagulation Inhibitors – Tissue Factor Pathway Inhibitor in Bleeding Disorders
- Plasma Coagulation Inhibitors – In Memory of Professor Elizabeth Van Cott
- Pediatric/Neonatal Thrombosis and Hemostasis – Update From Medication Adherence Working Group
- Control of Anticoagulation – Bleeding and Thrombotic Events After Resumption of Oral Anticoagulants Following Gastrointestinal Bleeding
- Control of Anticoagulation – First 5 Years of New Oral Anticoagulant Analyses at Karolinska University Laboratory – a Study of Patients With High and Low Drug Concentrations at a Tertiary Care Center
- Pediatric/Neonatal Thrombosis and Hemostasis – Update From Medication Adherence Working Group
- Platelet Physiology – Biomarkers of in Vivo Platelet Activation – a Systematic Review and Meta-Analysis
- Platelet Physiology – A Multicentric Comparison of Platelet Aggregation Agonists Against NIBSC Standards: An Update
- Platelet Physiology – Evaluation of the Isth Bleeding Assessment Tool (BAT) for the Assessment of Inherited Platelet Disorders: Individual-Level Meta-Analysis
- Factor XI and the Contact System – Assignment of FXII to SSC Lot #5 Plasma
- Factor XI and the Contact System – FXII Zymogen Contact Activation
- Factor XI and the Contact System – The Activated Partial Thromboplastin Time 2.0
- Factor XI and the Contact System – Comprehensive kinin quantification in human fluids by an innovative mass spectrometric platform
- Genomics in Thrombosis and Hemostasis – A Genome-Wide Association Study Meta-Analysis for Venous Thromboembolism
- Genomics in Thrombosis and Hemostasis – Variant Curation for Clinical Practice
- SSC Working Group on Hemostatic Management of Patients with Liver Disease – Animal Models of Hemostasis in Liver Disease - What Have We Learned?
- SSC Working Group on Hemostatic Management of Patients with Liver Disease – Risk Factors for Cirrhotic Portal Vein Thrombosis
- SSC Working Group on Hemostatic Management of Patients with Liver Disease – What Is the Current State of Trial Evidence for Alternatives to Plasma
- Disseminated Intravascular Coagulation – Disseminated Intravascular Coagulation in Patients With Cirrhosis - Need for Better Diagnostic Tools
- Disseminated Intravascular Coagulation – Disseminated Intravascular Coagulation and NETosis in Heparin Induced Thrombocytopenia
- Disseminated Intravascular Coagulation – Fibrinolytic Therapy for COVID-19
- Disseminated Intravascular Coagulation – Novel Biomarkers of Sepsis and Disseminated Intravascular Coagulation
- Models of Thrombosis and Hemostasis – In Vivo Imaging of Venous Thrombus and Pulmonary Embolism Using Novel Murine Venous Thromboembolism Model
- Models of Thrombosis and Hemostasis – Bleeding in Hypermobile Ehlers-Danlos Syndrome: Demand for Diagnostic and Prognostic Test Models for Bleeding
- Models of Thrombosis and Hemostasis – Preclinical Models of Transfusion-Related Acute Lung Injury
- Models of Thrombosis and Hemostasis – Preclinical Models of Platelet Allo-Immunization / Refractoriness
- Platelet Immunology and VITT – Results of the first EQA
- Platelet Immunology and VITT – The performance of immunoassays in VITT
- Platelet Immunology and VITT – Antibody Epitopes in Vaccine-Induced Immune Thrombotic Thrombocytopenia